Katherine Beebe DeVarney - 25 Oct 2023 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Reporting relationship: President and COO, Director
Issuer ticker: TTNP
Reported as of: 25 Oct 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Oct 2023, 16:25:57 UTC
Prior SEC filing: 28 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Katherine Beebe DeVarney

Key filing fact

Katherine Beebe DeVarney filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 26 Oct 2023.

Key facts

This page summarizes Katherine Beebe DeVarney's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Oct 2023, 16:25.

Change

Previous filing in this sequence was filed on 28 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TTNP transaction

Common Stock

Award

Transaction value: $0
Shares: +16,250
Change %: +32%
Price: $0.000000
Shares after: 66,250
Date: 25 Oct 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.